HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its CHT™ prepacked Foresight Pro Columns, designed to support downstream process-scale chromatography applications across different stages of biological drug development and production.
Foresight Pro Columns are manufactured in a controlled ISO Class 7 cleanroom, providing good manufacturing practice (GMP) ready columns. These columns are packed with CHT Ceramic Hydroxyapatite Media, a rigid mixed-mode support with unique separation properties used for the purification of biomolecules. The prepacked columns' standardized design and format offer a more cost-effective and flexible solution than customer-packed options and are available in a range of diameters and bed volumes.
"The Bio-Rad Foresight Pro Columns provide the biopharmaceutical industry with a convenient solution to improve the productivity of downstream bioprocessing from the early phases to the manufacturing-scale process," said Khaled Mriziq, PhD, Bio-Rad Senior Global Marketing Manager, Process Chromatography, Life Science Group. "Our prepacked GMP columns deliver consistent performance and eliminate the customer’s need to pack, qualify, and validate the columns."
To learn more about Bio-Rad Foresight Pro Columns, visit bio-rad.com/ForesightProColumn
BIO-RAD and CHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,900 employees worldwide. Bio-Rad had revenues of $2.9 billion in 2021. For more information, please visit bio-rad.com.
BIO-RAD and CHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc.
Dr. Khaled Mriziq, Bio-Rad Senior Global Marketing Manager, Process Chromatography
510-741-4651
khaled_mriziq@bio-rad.com
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com